P-360 Efficacy of regorafenib according to extended RAS evaluation: A multicenter retrospective analysis

Regorafenib has been shown to improve survival in later lines of treatment metastatic colorectal cancer patients, irrespective RAS status. This study aimed retrospectively assess the efficacy regorafenib relation extended evaluation a multi-center real-world setting. Nine Institution from Central-Southern Italy were involved study. Main inclusion criteria were: availability evaluation, data concerning time progression (TTP) and overall (OS). Primary endpoint was OS, independently line (>2), different mutations. Data 866 and/or TAS102-treated patients collected. available for 584. In present 324 have enrolled. Patients divided six groups: WT (RAS wild-type), 156 pts; Codon 12 (KRAS codon mutation), 82 13 23 Rare 61 146 mutation or NRAS mutations), 25 G12C G12c 7 G12D 26 pts. Baseline characteristics well-balanced between groups. No significant differences OS groups observed (p 0.6), with trend better favor mutated (median OS=12 m, 8 m G12D, when compared 6 WT). terms TTP 0.7). A toward 4.5 3.9 Rare) comparison 3.0 m) confirmed. Considering those who received TAS addition (either before after, 163 patients), an advantage 0.0002) suggesting favorable prognostic factors enriched population. According treated both displayed 0.05), performance (OS 10 m), 14 m). particular longer receiving even (before 78 pts vs 85 pts, p 0.0003). Differently, G12C, Rare, no only drugs. Our demonstrate that mutations do not affect outcome regorafenib-treated although observed. TAS102 after) show Regorafenib-related survival, probably because less aggressive disease; benefit combination is significantly higher subgroups. These data, bearing mind than 50% will receive drugs, might advise anticipation (compared 102) patients.